Smith D W, Ladefoged A, Reeser P, Edwards M
Tubercle. 1984 Jun;65(2):105-10. doi: 10.1016/0041-3879(84)90061-8.
We were unable to confirm the finding of Crowle that TESA possesses the attribute of immunogenicity and absence of allergenicity which are desired in a non-living antituberculosis vaccine. This disagreement could be a function of the particular lot of TESA examined and/or differences in the animal test systems used for the assay of protective potency. The relative contribution of these two possibilities could be determined by the simultaneous assay of a potent TESA product in different laboratories using different animal models.
我们无法证实克劳尔的研究结果，即结核杆菌提取物具有无活性抗结核疫苗所需的免疫原性和无变应原性属性。这种分歧可能是所检测的结核杆菌提取物特定批次的作用，和/或用于检测保护效力的动物试验系统的差异。这两种可能性的相对影响可以通过在不同实验室使用不同动物模型同时检测一种有效的结核杆菌提取物产品来确定。
